News & Updates

Show Multimedia Only

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Heart failure (HF) is a complicated clinical syndrome that is inherently progressive. In HF with reduced ejection fraction (HFrEF), the left ventricular ejection fraction (LVEF) is ≤40 percent and accompanied by progressive LV dilatation and adverse cardiac remodeling. [Eur J Heart Fail 2021;23:352-380]

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Management of allergic rhinitis – focus on Bilaxten

14 Jan 2022

Allergic rhinitis can induce two types of symptoms in patients: i) histamine-mediated symptoms such as vasodilatation, rhinorrhoea, itching and sneezing, and ii) allergic inflammation resulting from the action of eosinophils in the nasal lining. H1-antihistamine therapy is a mode of therapy that seeks to mitigate the histamine-mediated symptoms of allergic rhinitis; this therapy aims to relieve symptoms and to improve quality of life in patients.

Management of allergic rhinitis – focus on Bilaxten

14 Jan 2022

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

28 Dec 2021 by

Venous thromboembolism (VTE) is a serious medical condition. It comprises deep vein thrombosis and pulmonary embolism. Left untreated, it could result in significant morbidity and mortality. Most patients with VTE receive anticoagulation therapy for 3 months or longer. For more than 50 years since the 1940s, vitamin K antagonists (VKAs) such as warfarin were the mainstay of oral anticoagulation therapy for VTE. As it has a narrow therapeutic index, VKAs require frequent coagulation monitoring with International Normalised Ratio (INR) to adjust and optimize the dose for each individual. As the peak effect for warfarin takes at least 4-5 days, in the initial stage of VTE, concurrent administration of daily subcutaneous injections of low molecular weight heparin (LMWH) is needed until INR reaches therapeutic levels. Due to numerous drug and dietary interactions with warfarin, regular INR monitoring is required to ensure therapeutic levels are maintained and to avoid under or overdosing.

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

28 Dec 2021

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

28 Dec 2021 by

Nonvalvular atrial fibrillation (NVAF) raises the risk of stroke by three to five times, particularly in older patients. Treating older patients with NVAF presents special challenges because of their elevated risks for both stroke and bleeding. This necessitates optimization of anticoagulant therapy by balancing efficacy and bleeding risk. Non-vitamin K antagonist oral anticoagulants (NOACs), such as apixaban, have shown advantages in safety and efficacy over warfarin, which has a very narrow therapeutic index. In an interview with Dr Soon Chao Yang, Cardiologist at The Heart Doctors Clinic, Mount Alvernia Hospital, Singapore, he shared insights on managing NVAF in older patients, as well as his experience with using apixaban in this special population.

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

28 Dec 2021

Challenges and strategies in the management of MDRO infections in Asia

20 Dec 2021 by

Multidrug-resistant organisms (MDROs) are associated with a longer hospital stay, increased exposure to antimicrobial agents, and excess healthcare costs. Improved treatment and management strategies are urgently needed to curb the rising burden of MDROs in Asia. At a symposium organized by Pfizer in conjunction with the 18th Asia Pacific Congress of Clinical Microbiology and Infection (APCCMI 2021), experts discussed the role of rapid diagnostic testing and novel antibiotics in addressing MDRO infections, including practical solutions to maximize patient outcomes while minimizing the risk of antimicrobial resistance. The esteemed speakers were Professor Tobias Welte, Head, Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Germany, and Dr Asok Kurup, Infectious Diseases Consultant at Mount Elizabeth Medical Centre, Singapore. Professor Balaji Veeraraghavan, Head of the Department of Clinical Microbiology, Christian Medical College and Hospital, Vellore, India, chaired the session.

Challenges and strategies in the management of MDRO infections in Asia

20 Dec 2021

Management of ATTR-CM with tafamidis: Challenges and opportunities

08 Dec 2021 by

The advent of tafamidis ushers in a promising new era in the treatment and management of transthyretin amyloid cardiomyopathy (ATTR-CM), with longer-term clinical data attesting to its efficacy and safety. Despite this, ATTR-CM remains an easily overlooked and potentially fatal cause of heart failure. Furthermore, its elusive diagnosis often results in late or misdiagnosis. Clinical Assistant Professor Tang Hak Chiaw, Senior Consultant with the Department of Cardiology at the National Heart Centre Singapore, speaks on the challenges and opportunities on the diagnosis and management of ATTR-CM patients while sharing his experience of using tafamidis.

Management of ATTR-CM with tafamidis: Challenges and opportunities

08 Dec 2021

Clinical insights on best medical therapy for peripheral artery disease

02 Dec 2021 by

Patients with lower extremity peripheral artery disease (PAD) are at high risk for major adverse cardiovascular events (MACE), major adverse limb events (MALE), mortality, and future major lower extremity amputation (LEA). PAD patients with multivessel disease or relevant comorbidities such as diabetes and kidney failure are at an even higher risks for such events. [Lancet 2018;391:219-229]

Clinical insights on best medical therapy for peripheral artery disease

02 Dec 2021

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC

15 Nov 2021

Adding ribociclib (KISQALI, Novartis) to letrozole yields significant and consistent overall survival (OS) benefit compared with letrozole alone in the first-line setting for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), according to the final OS analysis of the MONALEESA-2 trial presented at ESMO 2021.

MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC

15 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

Vericiguat addresses unmet needs in worsening HFrEF

Vericiguat addresses unmet needs in worsening HFrEF

Management of allergic rhinitis – focus on Bilaxten

Management of allergic rhinitis – focus on Bilaxten

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

Challenges and strategies in the management of MDRO infections in Asia

Challenges and strategies in the management of MDRO infections in Asia

Management of ATTR-CM with tafamidis: Challenges and opportunities

Management of ATTR-CM with tafamidis: Challenges and opportunities

Clinical insights on best medical therapy for peripheral artery disease

Clinical insights on best medical therapy for peripheral artery disease

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC

MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC